A blinded in vitro study with Refacto® mock plasma samples: Similar FVII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution

Haemophilia

Volumn 8, Issue 5, 2002, Pages 639-643

  Caron, C ^a   Dautzenberg, M D ^b   Delahousse, B ^c   Droulle, C ^d   Pouzol, P ^d   Dubanchet, A ^b   Rothschild, C ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d SERVICE DE DERMATOLOGIE   (France)

Author keywords

Cephalin dilution; Chromogenic assay; Haemophilia A; One stage assay; Phospholipids; Recombinant FVIII

Indexed keywords

BLOOD CLOTTING FACTOR 8; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; DRUG DETERMINATION; DRUG PURIFICATION; HEMOPHILIA A; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; PRIORITY JOURNAL;

EID: 0036733367     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00666.x     Document Type: Article

References (14)

1. Recommendations for the assay of high-purity FVIII concentrates
2. Comparison of activity and antigen measurements in a pharmacokinetic study of recombinant factor VIII SQ
3. Assay discrepancies with highly purified factor VIII concentrates
4. Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay
5. In vivo recovery with products of very high purity - Assay discrepancies
6. Influence of phospholipids on the assessment of factor VIII activity
7. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family?
8. Use of a modified chronometric method for the assay of a new recombinant factor VIII in severe hemophilia A patients
9. Statistical methods for assessing agreement between two methods of clinical measurement
10. Discrepancies in potency assessment of recombinant FVIII concentrates
11. Plasma FVIII levels measured after infusion of recombinant FVIII (rFVIII) vary significantly with different assay methods - (will the real FVIII level please stand up!)
12. Discrepancy between one stage and chromogenic substrate assay. Results in the determination of FVIII recovery
13. Changes in membrane phospholipid distribution during platelet activation
14. Lipids of human leukocytes: Relation to cell type